NEW YORK (TheStreet) -- CHANGE IN RATINGS
was upgraded to buy at TheStreet Ratings.
was downgraded to hold at TheStreet Ratings.
earnings estimates were reduced at UBS. The lowered outlook reflects a sub-seasonal PC client trend, said UBS. Price target remains $22.50.
price target was increased to $105 by JPMorgan. Palbociclib (palbo, or PD-991), a breast cancer drug, is now included in the valuation, said JPMorgan.
price target was increased to $50 at Citigroup. The new price target reflects the likelihood of a significant debt raise, said Citigroup.
price target increased at Citi. The initial mid-term outlook provided at Z's fist analyst day led to a new price target of $70, said Citigroup.
( RHAT) estimates and price target cut at MKM. RHT earnings estimates through 2014 were reduced on management guidance, said MKM Partners. The new price target is $53.
price target was reduced to $29 at Benchmark. Lower fiscal 2Q guidance reflects uncertainty related to its ongoing business transformation, said Benchmark.
estimates and price target increased at JPMorgan. VRNT fourth quarter earnings were better than expected and outlook was solid, said JPMorgan. Earnings estimates were increased and the price target was bumped to $41.
estimates reduced at UBS on weaker than expected guidance from management. The new outlook includes investments for growth, said UBS. Price target remains $35.
estimates and price target were increased at KeyBanc to reflect a favorable lease pipeline. Price target goes to $68.
Bed Bath & Beyond
estimates reduced at Oppenheimer ahead of the earnings release. Sales and margin weakness have likely persisted, said Oppenheimer
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.